H
AYWARD, Calif.--Aventis CropScience of Lyon, France, has renewed its nonexclusive access to Lynx Therapeutics' genomics discovery services, limited to the agricultural field, for an additional year. The renewal includes payment of a fee for genomics discovery services to be performed by Lynx. Aventis CropScience initially obtained access to Lynx's services in March 1999, through activation of an existing agreement by their affiliate, Aventis Pharmaceuticals. In addition, Lynx and Aventis CropScience signed a three-year research collaboration agreement last September, which provides Aventis CropScience with exclusive access to Lynx's genomics technology for the study of certain plants, development of genomic maps, and the discovery of trait-associated single-nucleotide polymorphisms for the subject plants.